These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34172892)

  • 1. Itacitinib prevents xenogeneic GVHD in humanized mice.
    Courtois J; Ritacco C; Dubois S; Canti L; Vandenhove B; Seidel L; Daulne C; Caers J; Servais S; Beguin Y; Ehx G; Baron F
    Bone Marrow Transplant; 2021 Nov; 56(11):2672-2681. PubMed ID: 34172892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Xenogeneic Graft-Versus-Host Disease in Humanized NSG and NSG-HLA-A2/HHD Mice.
    Ehx G; Somja J; Warnatz HJ; Ritacco C; Hannon M; Delens L; Fransolet G; Delvenne P; Muller J; Beguin Y; Lehrach H; Belle L; Humblet-Baron S; Baron F
    Front Immunol; 2018; 9():1943. PubMed ID: 30214443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial.
    Zeiser R; Socié G; Schroeder MA; Abhyankar S; Vaz CP; Kwon M; Clausen J; Volodin L; Giebel S; Chacon MJ; Meyers G; Ghosh M; Deeren D; Sanz J; Morariu-Zamfir R; Arbushites M; Lakshminarayanan M; Barbour AM; Chen YB
    Lancet Haematol; 2022 Jan; 9(1):e14-e25. PubMed ID: 34971577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.
    Pratta M; Paczesny S; Socie G; Barkey N; Liu H; Owens S; Arbushites MC; Schroeder MA; Howell MD
    Br J Haematol; 2022 Aug; 198(4):729-739. PubMed ID: 35689489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Ry
    Burger DR; Parker Y; Guinta K; Lindner D
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):260-266. PubMed ID: 29128556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infusion of clinical-grade enriched regulatory T cells delays experimental xenogeneic graft-versus-host disease.
    Hannon M; Lechanteur C; Lucas S; Somja J; Seidel L; Belle L; Bruck F; Baudoux E; Giet O; Chantillon AM; Delvenne P; Drion P; Beguin Y; Humblet-Baron S; Baron F
    Transfusion; 2014 Feb; 54(2):353-63. PubMed ID: 23772685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of bone marrow-derived mesenchymal stromal cells on experimental xenogeneic graft-versus-host disease.
    Bruck F; Belle L; Lechanteur C; de Leval L; Hannon M; Dubois S; Castermans E; Humblet-Baron S; Rahmouni S; Beguin Y; Briquet A; Baron F
    Cytotherapy; 2013 Mar; 15(3):267-79. PubMed ID: 23265769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
    Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
    Front Immunol; 2021; 12():785774. PubMed ID: 34987512
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Establishment of Humanized Mice from Peripheral Blood Mononuclear Cells or Cord Blood CD34+ Hematopoietic Stem Cells for Immune-Oncology Studies Evaluating New Therapeutic Agents.
    Verma B; Wesa A
    Curr Protoc Pharmacol; 2020 Jun; 89(1):e77. PubMed ID: 32453514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human lymphocytes mobilized with exercise have an anti-tumor transcriptomic profile and exert enhanced graft-versus-leukemia effects in xenogeneic mice.
    Batatinha H; Diak DM; Niemiro GM; Baker FL; Smith KA; Zúñiga TM; Mylabathula PL; Seckeler MD; Lau B; LaVoy EC; Gustafson MP; Katsanis E; Simpson RJ
    Front Immunol; 2023; 14():1067369. PubMed ID: 37077913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vitro Th17-Polarized Human CD4
    Delens L; Ehx G; Somja J; Vrancken L; Belle L; Seidel L; Grégoire C; Fransolet G; Ritacco C; Hannon M; Dubois S; Beguin Y; Baron F; Servais S
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):204-215. PubMed ID: 30326279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of graft-versus-host-disease in NOD scid IL-2Rγ(-/-) (NSG) mice by ex vivo modulation of human CD4(+) T cells.
    Hilger N; Glaser J; Müller C; Halbich C; Müller A; Schwertassek U; Lehmann J; Ruschpler P; Lange F; Boldt A; Stahl L; Sack U; Oelkrug C; Emmrich F; Fricke S
    Cytometry A; 2016 Sep; 89(9):803-15. PubMed ID: 27560708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Itacitinib.
    Srinivas N; Barbour AM; Epstein N; Zhou G; Petusky S; Xun Z; Yuska B; Marbury T; Chen X; Yeleswaram S; Punwani N
    J Clin Pharmacol; 2020 Aug; 60(8):1022-1029. PubMed ID: 32149388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or parsaclisib in advanced solid tumors: a phase I study.
    Naing A; Powderly JD; Nemunaitis JJ; Luke JJ; Mansfield AS; Messersmith WA; Sahebjam S; LoRusso PM; Garrido-Laguna I; Leopold L; Geschwindt R; Ding K; Smith M; Berlin JD
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35288468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A human model of xenogeneic graft-versus-host disease in SCID mice engrafted with human peripheral blood lymphocytes.
    Sandhu JS; Gorczynski R; Shpitz B; Gallinger S; Nguyen HP; Hozumi N
    Transplantation; 1995 Jul; 60(2):179-84. PubMed ID: 7624960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective treatment of low-risk acute GVHD with itacitinib monotherapy.
    Etra A; Capellini A; Alousi A; Al Malki MM; Choe H; DeFilipp Z; Hogan WJ; Kitko CL; Ayuk F; Baez J; Gandhi I; Kasikis S; Gleich S; Hexner E; Hoepting M; Kapoor U; Kowalyk S; Kwon D; Langston A; Mielcarek M; Morales G; Özbek U; Qayed M; Reshef R; Rösler W; Spyrou N; Young R; Chen YB; Ferrara JLM; Levine JE
    Blood; 2023 Feb; 141(5):481-489. PubMed ID: 36095841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants.
    Gong X; Darpo B; Xue H; Punwani N; He K; Barbour AM; Epstein N; Landman R; Chen X; Yeleswaram S
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):677-688. PubMed ID: 31821750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Xenogeneic graft-versus-host-disease in NOD-scid IL-2Rγnull mice display a T-effector memory phenotype.
    Ali N; Flutter B; Sanchez Rodriguez R; Sharif-Paghaleh E; Barber LD; Lombardi G; Nestle FO
    PLoS One; 2012; 7(8):e44219. PubMed ID: 22937164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased splenic human CD4
    Geraghty NJ; Belfiore L; Adhikary SR; Alexander SI; Sluyter R; Watson D
    Transpl Immunol; 2019 Jun; 54():38-46. PubMed ID: 30743002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Xenogeneic Graft-Versus-Host Disease Model for Investigating the Pathological Role of Human CD4
    Ito R; Katano I; Kawai K; Yagoto M; Takahashi T; Ka Y; Ogura T; Takahashi R; Ito M
    Am J Transplant; 2017 May; 17(5):1216-1228. PubMed ID: 27862942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.